<DOC>
	<DOCNO>NCT03091634</DOCNO>
	<brief_summary>This multicenter , double-blind , randomize placebo-controled trial . purpose trial evaluate efficacy safety Xu-Fu-Zhu-Yu Capsule Treatment Qi Stagnation Blood Stasis syndrome ( QS &amp; BSS ) .QS &amp; BSS group symptoms sign human , pain fixed position , lumps body , irritability depression , dim complexion , unsmooth string-like pulse , purplish tongue petechia tongue . 's maladjustment body almost everyone would fall condition several time long period life . potential connection several kind disease , cardiovascular , endometriosis , fracture . Xu-Fu-Zhu-Yu capsule patent drug approve China Food Drug Administration . It derive ancient Chinese traditional medicine formula , use treat QS &amp; BSS almost 200 year . Experimental study show Xu-Fu-Zhu-Yu capsule treat many kind disease , coronary heart disease , insomnia , headache . And , patient QS &amp; BSS . So , research group plan randomize controlled trial evaluate efficacy safety Xu-Fu-Zhu-Yu Capsule Treatment QS &amp; BSS . total 120 paticipants randomly allocate either test group control group 1:1 ratio 3 site . All paticipants , different kind disease , give standard medical care accord guideline . Participants undergo 7-week treatment . primary outcome efficacy QS &amp; BSS improvement single symptom . secondary outcome change total score patient report outcome QS &amp; BSS ( PRO index ) . Safety outcomes include physical examination ( temperature , respiration , heart rate , blood pressure , height weight ) , complete blood cell count , urinalysis , stool examination , fecal occult blood test , liver function ( alanine aminotransferase ( ALT ) , aspartate transaminase ( AST ) , alkaline phosphatase ( ALP ) , serum total bilirubin ( STB ) , γ-glutamyl transpeptidase ( γ-GT ) ) , renal function ( serum creatinine ( SCr ) , blood urea nitrogen ( BUN ) , serum cystatin C , urine N-acetyl-β-glucosaminidase ) electrocardiogram ( ECG ) first , seventh week .</brief_summary>
	<brief_title>The Efficacy Safety Xu-Fu-Zhu-Yu Capsule Treatment Qi Stagnation Blood Stasis Syndrome .</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Blind Loop Syndrome</mesh_term>
	<criteria>1.the patient QS &amp; BSS ; 2.the age participant 18 65 ; 3.paticipants voluntarily sign informed consent . 1.paticipants diagnose acute myocardiac infarction , acute phase cerebral infarction , aortic dissection critically illness ; 2.paticipants poor control hypertension ( systolic pressure &gt; 160 millimeter mercury ( mmHg ) diastolic blood pressure &gt; 100mmHg ) , severe heart failure severe arrhythmia ( atrial fibrillation , atrial flutter , ventricular tachycardia , paroxysmal II type II atrioventricular block complete bundle branch block ) ; 3.paticipants severe primary disease heart , brain , liver , kidney hematopoietic system , liver function ALT AST value &gt; 1.5 time upper limit normal value , abnormal renal function ; 4.depression anxiety disorder paticipants ; 5.pregnant lactate woman ; 6.paticipants nerve mental illness , unwilling cooperate paticipants ; 7.paticipants perform surgery past 4 week ; 8.paticipants tendency bleed abnormal value difused intravascular coagulation ( DIC ) International standard ratio ( INR ) thrombocytopenia patient ; 9.paticipants join trial past 1 month ; 10.paticipants allergic test drug , people allergic constitution .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Xu-Fu-Zhu-Yu Capsule</keyword>
	<keyword>Qi Stagnation Blood Stasis syndrome</keyword>
	<keyword>National Center Complementary Integrative Health ( U.S . )</keyword>
</DOC>